Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 2/20 | 0.52 |
| ▸ | HTR3A | P46098 | 7/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5236631 | 0.79 | OPRM1 (0.55) | HTR3APOLBOPRM1OPRD1OPRK1 | |
| SCHEMBL5549623 | 0.76 | TOP2A (0.60) | TOP2AHTR3APOLBOPRD1OPRK1 | |
| SCHEMBL5232698 | 0.74 | PDE5A (0.45) | HTR3AOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL21547987 | 0.71 | OGFRL1 (0.74) | OPRM1OPRD1OPRK1OGFRL1 | |
| Hydrochloric Acid SCHEMBL5500127 | 0.71 | OPRM1 (0.55) | HTR3AOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL5497283 | 0.71 | ADRB1 (0.52) | HTR3AOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL9534952 | 0.71 | KCNH2 (0.61) | TOP2APOLBKDM4EALDH1A1HPGD | |
| SCHEMBL15139648 | 0.70 | PKM (0.70) | TOP2APOLBKDM4EALDH1A1HPGD | |
| SCHEMBL5166005 | 0.70 | MAPK1 (0.58) | KDM4EALDH1A1HPGD | |
| SCHEMBL7432371 | 0.69 | HTR3A (0.74) | HTR3AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244722-B2 | Amino-substituted 1H-pyrazin-2-ones and 1H-quinoxalin-2-ones | BIOVITRUM AB (SE) | 2007-07-17 | — | — | US | disclosed |
| EP-1534391-B1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| EP-1534391-A1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | Biovitrum AB (SE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040063693-A1 | Compounds | BIOVITRUM AB (SE) | 2004-04-01 | — | — | US | disclosed |
| WO-2004009586-A1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063693-A1 | Compounds | HTR1A, HTR1B, HTR2C | TOP2A 1397/4885HTR3A 11/4885POLB 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.